Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis
Pier Luigi Zinzani, Tatyana Feldman, Graham P. Collins, Jasmine Zain, Amit Khot, J. S. Kim, Franck Morschhauser, T. M. Kim, Justine E. Roderick, Jeong Lim Yoon, Shringi Sharma, Jamal Saeh, Jianrong Dai, R. Reyes, Richard F. Olsson, Jake Shortt (2023). Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis. , 41(S2), DOI: https://doi.org/10.1002/hon.3164_425.
Article155 days agoP1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS
Jake Shortt, Tatyana Feldman, Graham P. Collins, Jasmine Zain, Amit Khot, Jin Seok Kim, Franck Morschhauser, Tae Min Kim, Justine E. Roderick, Jeong Lim Yoon, Shringi Sharma, Jamal Saeh, Jiale Dai, Ruben Reyes, R A Olsson, Pier Luigi Zinzani (2023). P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS. , 7(S3), DOI: https://doi.org/10.1097/01.hs9.0000971460.41693.c0.
Article155 days agoSafety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
Youn H. Kim, M. Bagot, Pier Luigi Zinzani, Madeleine Duvic, Stephen Morris, Ellen Kim, Amy Musiek, Pablo L. Ortiz‐Romero, Craig A. Elmets, Herbert Eradat, Nina Magnolo, Julia Scarisbrick, Stéphane Dalle, David C. Fisher, Michi M. Shinohara, Brian Poligone, Barbara Pro, Pietro Quaglino, Nishitha Reddy, Brigitte Dréno, Larisa J. Geskin, Ahmad Halwani, Amit Khot, M. Beylot‐Barry, Neil J. Korman, Frederick Lansigan, Sarah McCue Horwitz, Zanetta S. Lamar, Alison J. Moskowitz, Jillian Wells, Oleg E. Akilov, Dolores Caballero, Richard Cowan, Reinhard Dummer, Mary Jo Lechowicz, Francine M. Foss, Lars Iversen, Tomomitsu Miyagaki, Ryan Wilcox, Pierluigi Porcu, Maarten H. Vermeer, Sunil Abhyankar, Yukihiko Kato, Theresa R. Pacheco, Shigetoshi Sano, Basem M. William, Timothy S. Fenske, Noriko Fukuhara, Koji Habe, Toshihisa Hamada, Eiji Kiyohara, Bryone J. Kuss, Adam Lerner, Lawrence A. Mark, Javier Muñoz, Hiroyuki Okamoto, Christiane Querfeld, Jiro Uehara, Hisashi Uhara, Kentaro Yonekura, Auris Huen, Kensei Tobinai, Y. Tokura, Erin Boh, Jan P. Nicolay, Hidefumi Wada, Mollie Leoni, Takahiro Ito, Fiona Herr, Lubomir Sokol (2019). Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. , 134(Supplement_1), DOI: https://doi.org/10.1182/blood-2019-122778.
Article155 days agoMogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa R. Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 19(9), DOI: https://doi.org/10.1016/s1470-2045(18)30379-6.
Article155 days agoAnti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study
Dmitri O. Grebennik, Kensei Tobinai, Madeline Duvic, Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Karen M. Dwyer, Junji Moriya, Jeffrey S. Humphrey, Stacie Hudgens (2017). Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. , 130(Suppl_1), DOI: https://doi.org/10.1182/blood.v130.suppl_1.817.817.
Article155 days ago